Sonoma Pharmaceuticals, Inc.
SNOA
$2.97
$0.051.71%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.16% | 13.58% | 31.05% | -1.05% | 14.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.16% | 13.58% | 31.05% | -1.05% | 14.10% |
| Cost of Revenue | -5.20% | 36.71% | 27.40% | -6.21% | 9.21% |
| Gross Profit | 40.05% | -13.01% | 37.47% | 8.47% | 26.27% |
| SG&A Expenses | -15.21% | 10.04% | 2.59% | -5.19% | 15.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.03% | 15.39% | 12.44% | -2.21% | 16.51% |
| Operating Income | 53.44% | -22.16% | 29.64% | 5.40% | -22.84% |
| Income Before Tax | 61.15% | 0.43% | 64.33% | 31.29% | 5.56% |
| Income Tax Expenses | 184.93% | 115.79% | -20.97% | 542.42% | -122.90% |
| Earnings from Continuing Operations | 27.27% | -7.16% | 58.89% | 19.39% | 18.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.27% | -7.16% | 58.89% | 19.39% | 18.43% |
| EBIT | 53.44% | -22.16% | 29.64% | 5.40% | -22.84% |
| EBITDA | 54.31% | -24.91% | 29.92% | 5.10% | -22.91% |
| EPS Basic | 65.42% | 60.03% | 89.74% | 76.64% | 77.33% |
| Normalized Basic EPS | 81.52% | 62.87% | 91.10% | 80.08% | 73.75% |
| EPS Diluted | 65.42% | 60.03% | 89.74% | 76.64% | 77.33% |
| Normalized Diluted EPS | 81.52% | 62.87% | 91.10% | 80.08% | 73.75% |
| Average Basic Shares Outstanding | 110.30% | 168.13% | 300.78% | 245.02% | 259.76% |
| Average Diluted Shares Outstanding | 110.30% | 168.13% | 300.78% | 245.02% | 259.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |